Apple Vision Pro-Assisted Vascular Identification in Lung Surgery (AVP-Lung)

May 1, 2026 updated by: Xiaohua Zuo, The Second People's Hospital of Huai'an

Apple Vision Pro-Assisted Vascular Identification in Lung Surgery: A Prospective Interventional Study

This study is testing whether a new mixed-reality head-mounted display (Apple Vision Pro) can help surgeons see blood vessels more clearly during lung surgery.

During the operation, doctors usually need to identify and protect important blood vessels to avoid bleeding. In this study, surgeons will wear the Apple Vision Pro device, which shows 3D images of the lungs and blood vessels. This may help them find vessels more accurately and make surgery safer.

Participants scheduled for lung surgery at Huai'an Second People's Hospital will be invited to join. Before the operation, participants will have a CT scan. During surgery, doctors will use the device while performing the procedure.

The study does not change the standard surgical steps, and there are no extra risks for participants. The main goal is to see if this new technology makes surgery easier and safer.

Participation is voluntary, and all personal information will be kept confidential.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Background:

Precise identification of pulmonary blood vessels is critical in thoracic surgery to prevent intraoperative bleeding and complications. Conventional methods rely on direct visual inspection and preoperative imaging review. Recent advances in extended reality (XR) technology offer potential for real-time, three-dimensional visualization during surgery.

Objective:

This study aims to evaluate the feasibility and safety of using Apple Vision Pro, a mixed-reality head-mounted display, to assist surgeons in identifying and navigating blood vessels during lung surgery.

Methods:

This is a single-center, prospective clinical study conducted at Huai'an Second People's Hospital. Patients undergoing elective lung surgery will be enrolled. All participants will receive standard preoperative chest CT scans.

During surgery, the surgical team will use Apple Vision Pro to visualize reconstructed 3D vascular models superimposed on the surgical field. The primary outcome is the accuracy of vessel identification and navigation. Secondary outcomes include operative time, blood loss, complication rates, and surgeon feedback on usability.

Ethical Considerations:

The study protocol has been approved by the Medical Ethics Committee of Huai'an Second People's Hospital. Informed consent will be obtained from all participants prior to enrollment.

Significance:

If successful, this study may provide a novel technological approach to improving surgical precision and safety in thoracic surgery.

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Chuxu Wang, Attending Physician
  • Phone Number: +86 15996195616
  • Email: wangchuxu@qq.com

Study Contact Backup

  • Name: Bo Min, Associate Professor
  • Phone Number: +86 18851392328
  • Email: doctor_min@163.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

Patients aged 18 years or older. Diagnosed with lung nodules or early-stage lung cancer requiring surgical resection (lobectomy or segmentectomy).

Scheduled for elective lung surgery at Huai'an Second People's Hospital. American Society of Anesthesiologists (ASA) Physical Status Classification I-III.

Ability to understand and sign the informed consent form. Willingness to undergo surgery with the Apple Vision Pro navigation assistance.

Exclusion Criteria:

Patients under 18 years of age. Pregnant or breastfeeding women. Patients with severe cardiopulmonary dysfunction (e.g., severe COPD, unstable angina, recent myocardial infarction) that would contraindicate surgery.

Participation in another interventional clinical trial within the past 30 days. Inability to cooperate with the surgical team or follow study procedures.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experimental
Participants in this arm will undergo lung surgery using Apple Vision Pro for intraoperative vascular navigation
Device: Apple Vision Pro
Use of Apple Vision Pro headset for augmented reality-assisted surgical navigation during lung surgery. The device will be worn by the surgeon to visualize critical anatomical structures and navigation pathways in real-time.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Accuracy of Perivascular Anatomical Identification
Time Frame: During the critical dissection and transection phase of lung surgery
The primary outcome is the accuracy of identifying critical perivascular anatomical structures (including pulmonary arteries, veins, and bronchi) using Apple Vision Pro. Accuracy will be measured by comparing the real-time navigation display with the actual anatomy confirmed by the surgeon during dissection. The primary endpoint is the successful identification of the correct transection plane that avoids injury to adjacent arteries, veins, or bronchi. Any discrepancy leading to potential mis-transection will be recorded.
During the critical dissection and transection phase of lung surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The Second People's Hospital of Huai'an

Investigators

  • Principal Investigator: Chuxu Wang, Attending Physician, The Second People's Hospital of Huai'an

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 1, 2026

Primary Completion (Estimated)

June 1, 2026

Study Completion (Estimated)

July 1, 2026

Study Registration Dates

First Submitted

April 24, 2026

First Submitted That Met QC Criteria

May 1, 2026

First Posted (Actual)

May 7, 2026

Study Record Updates

Last Update Posted (Actual)

May 7, 2026

Last Update Submitted That Met QC Criteria

May 1, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HEYLL202654

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

This is a single-center study with a limited sample size and specific local protocol. Due to resource constraints and the focus on immediate clinical outcomes for this specific cohort, data sharing is not planned at this time.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lung Neoplasms

Clinical Trials on Apple Vision Pro

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe